CSPC Pharmaceutical Group (HKG:1093) said China's National Medical Products Administration (NMPA) approved the clinical trial for its myasthenia gravis drug, according to a Friday filing with the Hong Kong bourse.
Myasthenia gravis is an autoimmune disease caused by autoantibodies directed against the neuromuscular junction. It is an mRNA-Lipid Nanoparticles (LNP)-based Chimeric Antigen Receptor (CAR)-T Cell Injection (SYS6020).
Price (HKD): $6.21, Change: $-0.020, Percent Change: -0.32%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments